Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Deffered Revenue: 2020-2023

Historic Non-Current Deffered Revenue for Janux Therapeutics (JANX) over the last 2 years, with Jun 2023 value amounting to $307,000.

  • Janux Therapeutics' Non-Current Deffered Revenue fell 94.20% to $307,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $307,000, marking a year-over-year decrease of 94.20%. This contributed to the annual value of $2.2 million for FY2022, which is 217.29% up from last year.
  • As of Q2 2023, Janux Therapeutics' Non-Current Deffered Revenue stood at $307,000, which was down 77.98% from $1.4 million recorded in Q1 2023.
  • In the past 5 years, Janux Therapeutics' Non-Current Deffered Revenue ranged from a high of $6.0 million in Q4 2020 and a low of $307,000 during Q2 2023.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $2.0 million (2021), whereas its average is $2.3 million.
  • Per our database at Business Quant, Janux Therapeutics' Non-Current Deffered Revenue skyrocketed by 217.29% in 2022 and then plummeted by 94.20% in 2023.
  • Quarterly analysis of 4 years shows Janux Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2020, then crashed by 88.43% to $700,000 in 2021, then surged by 217.29% to $2.2 million in 2022, then crashed by 94.20% to $307,000 in 2023.
  • Its last three reported values are $307,000 in Q2 2023, $1.4 million for Q1 2023, and $2.2 million during Q4 2022.